AXL Inhibitors: Status of Clinical Development.

Bhalla, Sheena; Gerber, David E

Bhalla, Sheena; Gerber, David E.

Bhalla S; Department of Internal Medicine (Division of Hematology-Oncology), UT Southwestern Medical Center, Dallas, TX, USA. sheena.bhalla@utsouthwestern.edu.
Gerber DE; Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX, USA. sheena.bhalla@utsouthwestern.edu.

Curr Oncol Rep ; 25(5): 521-529, 2023 05.

Article en En | MEDLINE | ID: mdl-36920638

Asunto(s)

Tirosina Quinasa del Receptor Axl; Neoplasias; Humanos; Proteínas Tirosina Quinasas Receptoras; Proteínas Proto-Oncogénicas/uso terapéutico; Transducción de Señal; Neoplasias/tratamiento farmacológico

Palabras clave

AXL; Cancer; GAS6/AXL signaling; Novel therapeutics; Targeted therapy

Texto completo

Imprimir

XML

PubMed Links

Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Tirosina Quinasa del Receptor Axl / Neoplasias Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Año: 2023 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Search on Google